News and Events

Pharmaceutical interest in nasal spray development continues to expand due to its unique advantages: rapid onset, non-invasive administration and suitability for both local and systemic therapies. As the market evolves, developers face increasing scientific and regulatory challenges that require a specialized approach. At Basic Pharma, we support partners throughout this process with end-to-end expertise in formulation, analysis and GMP nasal spray manufacturing.

Discover how sfGFP outperforms traditional GFP in folding efficiency, fluorescence stability, and biotech research applications.

Basic Pharma is excited to announce its participation in the Nordic Life Science Event 2025, taking place in Gothenburg, Sweden, on 13–14 October 2025. This premier gathering brings together industry leaders, researchers, and innovators who are shaping the future of life sciences and biotechnology.

The event is a cornerstone for networking, knowledge sharing, and discovering cutting-edge solutions that will define the next chapter of healthcare innovation.

We are pleased to announce that recombinant human Histone H3 is now available!

We are pleased to announce our partnership with Bio-Connect, a leading distributor of life science and diagnostic reagents in the Netherlands, Belgium, Luxembourg and throughout Europe.

We are happy to announce that the production of recombinant human Histone H3 is almost completed. In collaboration with Maastricht University, we have developed a

Basic Pharma is de trotse winnaar van de Brilliant Business Award in de categorie Innovatie (Diamond)! We zijn ontzettend trots op deze erkenning, niet alleen

We are delighted to share that Basic Pharma has been nominated for the esteemed Brilliant Business Award 2025, hosted by BrilliantBusiness.nl. This nomination recognises our

ARTES Biosciences and Basic Pharma are interested and proud to offer the first commercial samples of our joint recombinant human serum albumin (rHSA) production from

ARTES Biotechnology and Basic Pharma are almost there! Our joint project for the production of recombinant human serum albumin (rHSA) is nearing completion and the

Behind the scenes, we have been busy streamlining and consolidating our service offering to provide a clear snapshot of our capabilities for our customers.